


**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:


**LISTING OF CLAIMS:**

Claims 1-9 (canceled).

10. (previously presented): A glucopyranosyloxypyrazole derivative represented by the general formula:




wherein  $R^1$  represents a hydrogen atom or a lower alkyl group; one of  $Q^1$  and  $T^1$  represents a group represented by the formula:




while the other represents a lower alkyl group or a halo(lower alkyl) group;  $R^2$  represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or a pharmaceutically acceptable salt thereof.

11. (previously presented): A glucopyranosyloxypyrazole derivative as claimed in claim 10, represented by the general formula:




wherein R<sup>11</sup> represents a hydrogen atom or a straight-chained or branched alkyl group having 1 to 3 carbon atoms; one of Q<sup>11</sup> and T<sup>11</sup> represents a group represented by the formula:




while the other represents a straight-chained or branched alkyl group having 1 to 3 carbon atoms; and R<sup>21</sup> represents a straight-chained or branched alkyl group having 1 to 4 carbon atoms, a straight-chained or branched alkoxy group having 1 to 3 carbon atoms or a straight-chained or branched alkylthio group having 1 to 3 carbon atoms, or a pharmaceutically acceptable salt thereof.

- 3 12. (previously presented): A glucopyranosyloxypyrazole derivative as claimed in claim 10, represented by the general formula:



wherein R<sup>12</sup> represents a hydrogen atom, an ethyl group, a propyl group or an isopropyl group; one of Q<sup>12</sup> and T<sup>12</sup> represents a group represented by the formula:




while the other represents a methyl group; and  $R^{22}$  represents an ethyl group, an ethoxy group, an isopropoxy group or a methylthio group, or a pharmaceutically acceptable salt thereof.

4 13. (previously presented): A pharmaceutical composition comprising as an active ingredient a glucopyranosyloxypyrazole derivative as claimed in claim 10, or a pharmaceutically acceptable salt thereof.

5 14. (previously presented): A pharmaceutical composition as claimed in claim 13 wherein the composition is a human SGLT2 inhibitor.


6 15. (previously presented): A glucopyranosyloxypyrazole derivative represented by the general formula:



wherein  $R^1$  represents a hydrogen atom or a lower alkyl group; one of  $Q^2$  and  $T^2$  represents a 2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-glucopyranosyloxy group, while the other represents a lower alkyl group or a halo(lower alkyl) group; and  $R^2$  represents a hydrogen atom, a lower alkyl group, a

lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or a salt thereof.

16. (previously presented): A benzylpyrazole derivative represented by the general formula:



wherein R<sup>2'</sup> represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and R<sup>3'</sup> represents a lower alkyl group, or a salt thereof.

7 17. (previously presented): A pharmaceutical composition comprising as an active ingredient a glucopyranosyloxypyrazole derivative as claimed in claim 11, or a pharmaceutically acceptable salt thereof.

8 18. (previously presented): A pharmaceutical composition comprising as an active ingredient a glucopyranosyloxypyrazole derivative as claimed in claim 12, or a pharmaceutically acceptable salt thereof.

9 19. (previously presented): A method for treating diabetes in a subject, which comprises administering to the subject an amount of the compound as claimed in claim 10, or a pharmaceutically acceptable salt thereof, effective to treat diabetes in the subject.

AMENDMENT UNDER 37 C.F.R. § 1.312  
U.S. Application No.: 10/759,138

10 20. (previously presented): A method for treating diabetes in a subject, which comprises administering to the subject an amount of the compound as claimed in claim 11, or a pharmaceutically acceptable salt thereof, effective to treat diabetes in the subject.

11 21. (previously presented): A method for treating diabetes in a subject, which comprises administering to the subject an amount of the compound as claimed in claim 12, or a pharmaceutically acceptable salt thereof, effective to treat diabetes in the subject.

12 22. (previously presented): A method for treating obesity in a subject, which comprises administering to the subject an amount of the compound as claimed in claim 10, or a pharmaceutically acceptable salt thereof, effective to treat obesity in the subject.

13 23. (previously presented): A method for treating obesity in a subject, which comprises administering to the subject an amount of the compound as claimed in claim 11, or a pharmaceutically acceptable salt thereof, effective to treat obesity in the subject.

14 24. (previously presented): A method for treating obesity in a subject, which comprises administering to the subject an amount of the compound as claimed in claim 12, or a pharmaceutically acceptable salt thereof, effective to treat obesity in the subject.

15 25. (previously presented): A method for increasing the amount of urinary glucose excretion in a subject in need thereof, which comprises administering to the subject an amount of the compound as claimed in claim 10, or a pharmaceutically acceptable salt thereof, effective to increase the amount of urinary glucose excretion in the subject.

AMENDMENT UNDER 37 C.F.R. § 1.312  
U.S. Application No.: 10/759,138

16 26. (previously presented): A method for increasing the amount of urinary glucose excretion in a subject in need thereof, which comprises administering to the subject an amount of the compound as claimed in claim 11, or a pharmaceutically acceptable salt thereof, effective to increase the amount of urinary glucose excretion in the subject.

17 27. (previously presented): A method for increasing the amount of urinary glucose excretion in a subject in need thereof, which comprises administering to the subject an amount of the compound as claimed in claim 12, or a pharmaceutically acceptable salt thereof, effective to increase the amount of urinary glucose excretion in the subject.

18 28. (currently amended): A method for lowering blood glucose concentration in a subject in need thereof, which comprises administering to the subject an amount of the compound as claimed in claim 10, or a pharmaceutically acceptable salt thereof, effective to lower blood glucose concentration in the subject.

19 29. (currently amended): A method for lowering blood glucose concentration in a subject in need thereof, which comprises administering to the subject an amount of the compound as claimed in claim 11, or a pharmaceutically acceptable salt thereof, effective to lower blood glucose concentration in the subject.

20 30. (currently amended): A method for lowering blood glucose concentration in a subject in need thereof, which comprises administering to the subject an amount of the

AMENDMENT UNDER 37 C.F.R. § 1.312  
U.S. Application No.: 10/759,138

compound as claimed in claim 12, or a pharmaceutically acceptable salt thereof, effective to  
lower blood glucose concentration in the subject.